Arrhythmias is a new study from Decision Resources, Inc. The term arrhythmias encompasses a wide range of conduction anomalies, from those that are benign (extra beats) to those that are a chronic cause of suffering (atrial fibrillation [AF]) to those that are deadly (ventricular tachycardia [VT] and ventricular fibrillation [VF]). Arrhythmias (particularly AF) represent an area of untapped potential and are of keen interest to the pharmaceutical industry for the following reasons:

( Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

  -- The large patient population.   -- The high rate of drug treatment.   -- The need for therapies to effectively prevent the recurrence of AF and      other arrhythmias.   -- The need for nonpharmacological alternatives.   -- The need for safer drugs.  

We predict that major-market (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) sales of drugs to manage arrhythmias will increase modestly throughout the 1999-2009 forecast period of this study, growing from nearly $1.8 billion in 1999 to $2.1 billion in 2004 and almost $2.6 billion in 2009. The principal drivers of this growth will be small increases in prevalence and diagnosis rates in most countries, a higher use of device/drug combination therapy, and the uptake of expensive novel therapies. Key trends include the following:

-- An exciting area in arrhythmia drug development is the investigation of novel anticoagulants, which show promise as an alternative to warfarin (DuPont's Coumadin, generics). As physicians in all the major markets increasingly prescribe anticoagulants over the study period, the growth opportunity for these new agents will be tremendous.

-- New devices and techniques will continue to grow in popularity for all arrhythmias, reducing the overall proportion of drug-treated patients. New opportunities for drugs will arise, however, as adjuncts to device implantation.

-- Class I drug market share will be taken up by existing Class III drugs and to a greater extent by novel Class III drugs. Growing evidence of amiodarone's (Sanofi-Synthelabo/American Home Products' Cordarone) efficacy and the anticipated safety level of newer drugs will be the key growth drivers.

Arrhythmias is part of Cardium, a multiclient service that evaluates the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or sama@dresources.com (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), fbidart@decisionresources.be (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,
sama@dresources.com

Decision Resources Report Reveals Patterns and Trends in Central Nervous System and Psychiatric Drug Development

View Now